TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03151421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home air quality monitoring and feedback
Description: Two-hundred smokers (50 in each country) will be recruited and offered low-cost, simple to operate particle counting instruments to measure and log SHS levels in their home for a period of 30 days. During this time near real-time, personalised feedback will be provided to, and discussed with, the smoker along with target-setting and exploration of suitable methods of behaviour-change. Feedback will be given via text message to mobile phones, emails and personal voicecalls. A final visit will gather data on changes made while a proportion of participants (10-20%) in each country will take part in a further qualitative interview by phone to gather data on their experience of the intervention.
Study: NCT02349113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogens (Climara)
Description: Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
Study: NCT04798703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
Description: 12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase) followed by maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months in patients who achieved a complete response (CR) after the 12 weekly instillations.
Study: NCT01427907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium acetate oral solution (COS)
Description: Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Description: Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
Study: NCT02402179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
Study: NCT03783533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Intervention: Behavioral Activation (BA) therapy is based on a functional analytic model of depression that highlights the need for increased positive reinforcement (rewards) and decreased anhedonia, or diminished motivation to seek rewards, to maintain normal mood. BA is significantly more effective than Cognitive Behavioral Therapy and comparable to antidepressant medication in reducing depressive symptoms among depressed adults (Dimidjian et al., 2006). McCauley (senior mentor) et al. (2016) adapted BA for adolescents to target anhedonia, effective problem solving and avoidant behaviors with peers, family, and school. McCauley's findings and others show BA is a promising intervention for adolescent MDD (Chu et al., 2009; Cuijpers et al.,, 2007; McCauley et al., 2015; Ritschel et al., 2011). BA focuses on targeting ideographically identified avoidant behaviors and rewarding experiences that affect mood.
Study: NCT00591747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Training
Description: 60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
Study: NCT02815631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiogoniometry (CGM)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Flow Reserve (FFR)
Study: NCT03987581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management (mCM)
Description: Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management (mCM)
Description: Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long-term incentive
Description: This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long-term incentive
Description: This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
Study: NCT01994733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate ( Intensive phosphate control)
Description: Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of \< 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate (Liberalized phosphate control)
Description: Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L.
Study: NCT03417973

Intervention type: DEVICE
Intervention: dorsal root ganglion neuromodulation
Description: stimulation for neuromodulation of the dorsal root ganglion

Intervention type: DEVICE
Intervention: dorsal root ganglion neuromodulation
Description: stimulation for neuromodulation of the dorsal root ganglion
Study: NCT00293462

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Study: NCT01149278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maintain mean arterial pressure between 80-85 mm Hg
Description: protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maintain mean arterial pressure between 65-70 mm Hg
Description: protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
Study: NCT02559232

Intervention type: DRUG
Intervention: Direct Oral Anticoagulant (DOAC)
Description: Treatment pattern following the summary of product characteristics
Study: NCT01912872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Subcutaneous injection dose according to the IgE level and body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
Study: NCT00293462

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral salt and soda mouthwash
Description: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral salt and soda mouthwash
Description: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
Study: NCT03393520

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules
Study: NCT01912872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12ug tablets taken orally according to maximum daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Formoterol 12ug tablets taken orally according to maximum daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
Study: NCT02205385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traction Neurectomy
Study: NCT03042611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Oral tablet
Study: NCT03973489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
Study: NCT03393520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules
Study: NCT01628874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Tip
Description: Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: J-Tip
Description: Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
Study: NCT03042611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet
Study: NCT01628874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
Study: NCT01495897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracking eye movement under deep brain stimulation
Description: Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
Study: NCT01869894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metallic biliary stent insertion (double bare - S&G Biotech.)
Description: The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metallic biliary stent insertion (single bare - S&G Biotech.)
Description: The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metallic biliary stent insertion (single bare - Taewoong Medical.)
Description: The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
Study: NCT05222347

Intervention type: DIETARY_SUPPLEMENT
Intervention: Olive Leaf Tea
Description: Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently \[22, 23\]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects \[24, 25\]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .

Intervention type: DIETARY_SUPPLEMENT
Intervention: Olive Leaf Tea
Description: Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently \[22, 23\]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects \[24, 25\]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .
Study: NCT01947374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Matrix encapsulated chondrocyte implantation
Description: Each implant contains 6,000,000 autologous chondrocytes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture awl
Description: Is an awl that allow perforation of the subchondral bone.
Study: NCT02485366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rejuvesol
Description: Blood transfused during surgery will be treated with Rejuvesol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Description: The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
Study: NCT04150640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-IRI
Description: chemotherapy drug
Study: NCT01628874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
Study: NCT01579617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BUtiful.
Description: 8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DIVAS.
Description: Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
Study: NCT00795418

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106
Study: NCT01663675

Intervention type: GENETIC
Intervention: karyotype
Study: NCT02382601

Intervention type: RADIATION
Intervention: Pediatric heart ultrasound
Description: Children will have ultrasounds of their hearts during follow-up visits.
Study: NCT04132284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-Based Parenting Intervention
Description: The intervention will consist of 8-10 individual parent sessions, to be completed within one week after the teen completes the IOP program. Sessions will be 1 hour in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 10. Sessions will follow the standard agenda used for DBT skills training: 1) mindfulness practice, 2) homework review, 3) teaching of a new skill; 4) practice of the new skill; and 5) assignment of new homework (Linehan, 1993). The intervention will utilize the Middle Path module of the DBT Skills Manual for Adolescents (Rathus \& Miller, 2015), which was created by the developers of DBT for adolescents and includes both instructions for therapists and handouts for clients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: No parenting intervention provided beyond standard practices in DBT IOP program.
Study: NCT04150640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-IRI
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-IRI
Description: chemotherapy drug
Study: NCT02433093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basimglurant
Description: Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.